# aTyr Pharma: Biotechnology, San Diego, United States

> aTyr Pharma: aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...

Source: https://millionrounds.com/startup/atyr-pharma (Millionrounds; every figure on the page links to its filing or article)

United States · [Biotechnology startup](https://millionrounds.com/companies)

# aTyr Pharma

aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

Listed

Biotechnology San Diego, United States

Company summary

- **Founded:** - not reported
- **Team:** 82 51 to 200 people
- **Funding reported:** - none reported
- **Last round:** - date not reported

How sure we are

- 1 **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for aTyr Pharma has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About aTyr Pharma

aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.

## Founders and team

From the SEC filings it signed: 5 on the team.

- **John D. Mendlein** Executive Officer, Director i
- **John T. Blake** Executive Officer i
- **Nancy D. Krueger** Executive Officer i
- **Sanjay S. Shukla** Executive Officer i
- **Sanuj K. Ravindran** Executive Officer i

On the board, as filed i *Amir H. Nashat* *James C. Blair* *Jeffrey S. Hatfield* *John K. Clarke* *Mark P. Goldberg* *Paul K. Schimmel* *Srini S. Akkaraju* *Timothy P. Coughlin*

## On 2 portfolio pages

Investors who name them

- [EcoR1 Capital](https://millionrounds.com/fund/ecor1-capital)
- [Cardinal Partners](https://millionrounds.com/fund/cardinal-partners-cp-venture-capital)

Each firm lists aTyr Pharma on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## Biotechnology in United States

Startups like it

- [**Sojournix** Waltham · founded 2016 *Raised*](https://millionrounds.com/company/sojournix)
- [**Receptor Life Sciences** Seattle · founded 2017 *Raised*](https://millionrounds.com/company/receptor-life-sciences)
- [**Attune Pharmaceuticals** New York · founded 2018 *Raised*](https://millionrounds.com/company/attune-pharmaceuticals)
- [**AbbVie** North Chicago · founded 2012](https://millionrounds.com/startup/abbvie-2)
- [**Grail** Menlo Park · founded 2015](https://millionrounds.com/startup/grail-3)
- [**EQRx** Cambridge · founded 2019](https://millionrounds.com/startup/eqrx)
- [**Cerevel Therapeutics** Boston · founded 2018](https://millionrounds.com/startup/cerevel-therapeutics)
- [**Royalty Pharma** New York · founded 1996](https://millionrounds.com/startup/royalty-pharma)

## Is this your company?

Add your raise, your deck and your story, and put aTyr Pharma in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)